Paul Hughes, Ph.D.Scientific Director at Amgen
Profile
Since joining Amgen in 2003 my research has been focused on the discovery of novel small and large molecule oncology therapeutics. My group contributed to the discovery of AMG 757, a first-in-class DLL3-targeted bispecific T-cell engager molecule BITE molecule targeting DLL3. I’m currently actively engaged in cross-functional teams to develop novel targeted therapies focused on drugging proteins that are genetically altered in cancer.
Agenda Sessions
Advances in T-Cell Engaging Therapies
12:30View SessionPreclinical Activity of the DLL3-targeting BiTE Molecule AMG 757 in Small Cell Lung Cancer
On DemandView Session